NEW YORK (GenomeWeb News) - Geron licensed its intellectual property related to the growth of human embryonic stem cells to Invitrogen, Invitrogen said today.
Under the non-exclusive license agreement, Invitrogen can use Geron's patents to develop, manufacture, and sell media, additives, and reagents for use by hESC researchers. Some commercial use restrictions apply.
Invitrogen can also sublicense the products to its customers for research use only. Geron will receive license payments and royalties on products developed using the patents.
The license involves patents covering the growth of hESCs in the absence of feeder cells, and those covering specific media formulations for such feeder-free growth.
Additional financial details were not disclosed.